Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (LLY) reported strong financial results for Q4 and the full year 2021, showcasing an 8% revenue increase in Q4 to $8 billion and a 15% annual growth to $28.3 billion. The company highlighted significant growth in key products, including Trulicity and Taltz. However, net income decreased by 18% in Q4 and 10% for the year, primarily due to reduced other income and increased operating expenses. Lilly continues to pursue an exciting pipeline and expects 2022 EPS in the range of $8.00 to $8.15, affirming confidence in future growth.
Eli Lilly and Company (NYSE: LLY) has partnered with UNICEF to improve health outcomes for 10 million children and adolescents suffering from chronic non-communicable diseases (NCDs) by 2025. Lilly will contribute $14.4 million to enhance healthcare systems and support health workers in Bangladesh, Malawi, Nepal, the Philippines, and Zimbabwe. This collaboration aims to combat diseases like diabetes and cancer, addressing the crisis where nearly one million children under 20 die annually due to often treatable conditions.
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on February 9, 2022. Key figures, including Jake Van Naarden, CEO of Loxo Oncology at Lilly, and David Hyman, M.D., Chief Medical Officer of Lilly Oncology, will engage in a virtual fireside chat at 12 p.m. Eastern time. Investors can access a live audio webcast through Lilly's Investor website, with a replay available for approximately 90 days thereafter. Eli Lilly remains committed to discovering life-changing medicines and giving back to communities.
Eagle Pharmaceuticals has launched PEMFEXY (pemetrexed for injection), a new treatment for nonsquamous non-small cell lung cancer and mesothelioma. Sales started today, following FDA approval and a settlement with Eli Lilly. The U.S. market for ALIMTA, a competitor, reached $1.2 billion in the past year. The company anticipates substantial revenue growth from PEMFEXY in 2022. With a unique J-code, PEMFEXY is positioned to benefit both patients and providers in the oncology market.
Eli Lilly plans to invest over $1 billion in a new manufacturing site in Concord, North Carolina, creating nearly 600 new jobs. This facility aims to enhance manufacturing capacity for injectable products and leverage advanced technology. The decision reflects Lilly's commitment to growth in the pharmaceutical sector and its ongoing investments in North Carolina, totaling over $4 billion in the past five years. The investment is contingent on local government approvals, and an additional $500 million will be spent on a biopharmaceutical facility in Ireland.
Eli Lilly and Incyte provided updates on the Phase 3 development for OLUMIANT (baricitinib) in systemic lupus erythematosus (SLE) and atopic dermatitis. The Phase 3 lupus program has been discontinued after the SLE-BRAVE-I study met its primary endpoint, while SLE-BRAVE-II did not. Ongoing discussions with the FDA may lead to a Complete Response Letter for the atopic dermatitis sNDA due to lack of alignment on the indicated population. Lilly remains committed to other research with OLUMIANT, including potential regulatory approvals for COVID-19 and alopecia areata in 2022.
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on February 3, 2022. A conference call is scheduled for 9 a.m. Eastern time on the same day, accessible via a live webcast on Lilly's website. The call will provide detailed insights into the company's financial performance for the year. Investors and the public are invited to participate, and a replay will be available afterward.
Eli Lilly and Company (NYSE: LLY) will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2022. David A. Ricks, chairman and CEO, will engage in a virtual fireside chat at 4:30 p.m. Eastern Time. Interested parties can listen to the live audio webcast on Lilly's Investor website, with a replay available for approximately 30 days thereafter. Lilly, a global healthcare leader, continues its mission to develop medicines that improve lives worldwide. More information can be found at www.lilly.com.
Eli Lilly has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology. This partnership aims to develop nucleic acid products targeting the central and peripheral nervous systems. Lilly will invest $50 million upfront and may pay up to $400 million in milestones, alongside royalties on successful products. The collaboration seeks to address significant challenges in nucleic acid-based therapies. Despite this acquisition, Lilly's non-GAAP earnings guidance for 2021 and 2022 remains unchanged.
Eli Lilly's lebrikizumab, an IL-13 inhibitor, showed significant improvement in atopic dermatitis (AD) severity when combined with topical corticosteroids in the third pivotal Phase 3 trial (ADhere). By Week 16, all primary and key secondary endpoints were met, including substantial skin improvement and itch relief. Safety results were consistent with prior studies, with common adverse events like conjunctivitis. Pending completion of ongoing trials, regulatory submissions are expected in 2022, enhancing treatment options for patients with moderate-to-severe AD.